Drug-induced immune thrombocytopenic purpura secondary to sunitinib

Curr Oncol. 2008 Jun;15(3):152-4. doi: 10.3747/co.v15i3.233.

Abstract

SUNITINIB (SUTENT: Pfizer, New York, NY, U.S.A.) is an oral multi-targeted tyrosine kinase inhibitor approved for use in various solid tumour malignancies. Many side effects secondary to sunitinib have been documented. In particular, sunitinib administration is known to result in thrombocytopenia, with the cause being attributed to myelosuppression. Here, we present the first case report to demonstrate immune-mediated thrombocytopenia secondary to sunitinib administration.

Keywords: Breast cancer; sunitinib; thrombocytopenia.